点击图片查看原图
| Ts-C204-09 | 重组人 FGF-9 | Recombinant Human FGF-9 | 5μg |
| Ts-C204-09 | 重组人 FGF-9 | Recombinant Human FGF-9 | 20μg |
| Ts-C204-09 | 重组人 FGF-9 | Recombinant Human FGF-9 | 1000μg |
| Ts-C204-10 | 重组人 KGF-2 (FGF-10) | Recombinant Human KGF-2 (FGF-10) | 5μg |
| Ts-C204-10 | 重组人 KGF-2 (FGF-10) | Recombinant Human KGF-2 (FGF-10) | 25μg |
| Ts-C204-10 | 重组人 KGF-2 (FGF-10) | Recombinant Human KGF-2 (FGF-10) | 1000μg |
| Ts-C204-13 | 重组人 FGF-13 | Recombinant Human FGF-13 | 5μg |
| Ts-C204-13 | 重组人 FGF-13 | Recombinant Human FGF-13 | 20μg |
| Ts-C204-13 | 重组人 FGF-13 | Recombinant Human FGF-13 | 1000μg |
| Ts-C204-18 | 重组人 FGF-18 | Recombinant Human FGF-18 | 5μg |
| Ts-C204-18 | 重组人 FGF-18 | Recombinant Human FGF-18 | 25μg |
| Ts-C204-18 | 重组人 FGF-18 | Recombinant Human FGF-18 | 1000μg |
| Ts-C204-19 | 重组人 FGF-19 | Recombinant Human FGF-19 | 5μg |
| Ts-C204-19 | 重组人 FGF-19 | Recombinant Human FGF-19 | 25μg |
| Ts-C204-19 | 重组人 FGF-19 | Recombinant Human FGF-19 | 1000μg |
| Ts-C204-21 | 重组人 FGF-21 | Recombinant Human FGF-21 | 5μg |
| Ts-C204-21 | 重组人 FGF-21 | Recombinant Human FGF-21 | 25μg |
| Ts-C204-21 | 重组人 FGF-21 | Recombinant Human FGF-21 | 1000μg |
| Ts-C204-23 | 重组人 FGF-23 | Recombinant Human FGF-23 | 5μg |
| Ts-C204-23 | 重组人 FGF-23 | Recombinant Human FGF-23 | 20μg |
| Ts-C204-23 | 重组人 FGF-23 | Recombinant Human FGF-23 | 1000μg |
Human Fibroblast Growth Factor-19
Source: Escherichia coli.
Source: Escherichia coli.
Molecular Weight: Approximately 21.8 kDa, a single non-glycosylated polypeptide chain containing 195 amino acids.
Quantity: 5µg/25µg/1000µg
AA Sequence: MRPLAFSDAG PHVHYGWGDP IRLRHLYTSG PHGLSSCFLR IRADGVVDCA RGQSAHSLLE IKAVALRTVA IKGVHSVRYL CMGADGKMQG LLQYSEEDCA FEEEIRPDGY NVYRSEKHRL PVSLSSAKQR QLYKNRGFLP LSHFLPMLPM
VPEEPEDLRG HLESDMFSSP LETDSMDPFG LVTGLEAVRS PSFEK
Purity: > 95 % by SDS-PAGE and HPLC analyses.
Biological Activity: Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation
assay using murine Balb/c 3T3 cells is less than 150 ng/ml, corresponding to a specific activity of > 6.7 × 103 IU/mg.
Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation: Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.
Endotoxin: Less than 1 EU/µg of rHuFGF-19 as determined by LAL method.
Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Storage: This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.
Usage: This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further
evaluation purposes. NOT FOR HUMAN USE.